Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 30 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $11.2K | 0.00% | 11.40K | −12% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RNXT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | Voll MarkChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 80K | — |
| May 18, 2026 | Voll MarkChief Financial Officer | Purchase at price 0.79 per share. | 25K | $19.69K |
| Apr 1, 2026 | Voll MarkChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 80K | — |
| Mar 24, 2026 | Voll MarkChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 12.4K | — |
| Mar 19, 2026 | Voll MarkChief Financial Officer | Purchase at price 1.00 per share. | 97.2K | $97.20K |
| Mar 19, 2026 | Marton LaurenceDirector | Purchase at price 1.00 per share. | 9.7K | $9.72K |
| Mar 19, 2026 | Bagai Shaun R.Chief Executive Officer | Purchase at price 1.00 per share. | 24.3K | $24.30K |
| Jan 20, 2026 | Agah Ramtin M.D.Officer and Director | Purchase at price 1.00 per share. | 10K | $9.97K |
| Dec 30, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.86 per share. | 9.8K | $8.42K |
| Dec 29, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.83 per share. | 205 | $169 |
| Dec 17, 2025 | Bagai Shaun R.Chief Executive Officer | Purchase at price 0.90 per share. | 5K | $4.51K |
| Dec 16, 2025 | Bagai Shaun R.Chief Executive Officer | Purchase at price 0.85 per share. | 5K | $4.26K |
| Dec 15, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.85 per share. | 12K | $10.20K |
| Dec 4, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.96 per share. | 10K | $9.60K |
| Nov 23, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.80 per share. | 22K | $17.60K |
| Aug 24, 2025 | Bagai Shaun R.Chief Executive Officer | Purchase at price 0.91 - 0.95 per share. | 10K | $9.30K |
| Jun 4, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 1.40 per share. | 21K | $29.40K |
| May 1, 2025 | Marton LaurenceDirector | Conversion of Exercise of derivative security at price 0.15 per share. | 20.5K | $3.07K |
| Apr 21, 2025 | Agah Ramtin M.D.Officer and Director | Stock Gift at price 0.00 per share. | 400K | — |
| Apr 14, 2025 | Agah Ramtin M.D.Officer and Director | Purchase at price 0.90 per share. | 15K | $13.50K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.8 | -15.1 | 14.4 | -15.8 | 6.9 | 7.8 | -2.2 | 101.5 | -19.2 | -26.3 | +36.9% | ||
| 2025 | 5.4 | -26.5 | -1.0 | -3.0 | 45.8 | -6.1 | -5.7 | -22.6 | 32.3 | -12.6 | -17.4 | -8.4 | −34.9% |
| 2024 | -34.5 | 14.7 | -22.1 | -9.7 | -4.1 | -2.6 | 6.2 | -15.0 | 3.9 | -5.8 | 27.3 | 1.6 | −43.7% |
| 2023 | 11.9 | 76.8 | -25.1 | -10.2 | -40.6 | 21.5 | -12.4 | -18.2 | -17.9 | -14.3 | -43.9 | 257.8 | −2.6% |
| 2022 | -31.4 | 1.2 | -12.8 | -43.0 | 17.4 | 1.0 | -1.8 | 8.0 | -3.8 | -13.4 | 11.4 | 20.5 | −51.4% |
| 2021 | -39.5 | -14.2 | 36.7 | -31.6 | −51.6% |
Buy / hold / sell counts
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.